Patients (72.5 ± 9.7 y/o, 61% females, EuroSCORE-II: 5.7 ± 5.7%, p > 0.05 for all) presented with advanced symptoms of HF (NYHA ≥III: TMVR 86 vs. SMV 77%, p = 0.255), NT-proBNP (TMVR: 3608 vs. SMV: 2192 pg/mL, p = 0.535), and renal function (estimated glomerular filtration rate (eGFR): TMVR: 59 vs. SMV: 69 mL/min/1.73 m2, p = 0.068). This evidence concerns the gene NPPB and hydrops fetalis.